The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies
Open accessPublished version of a preprint
Abstract
The SWI/SNF multisubunit complex modulates chromatin structure through the activity of two mutually exclusive catalytic subunits, SMARCA2 and SMARCA4, which both contain a bromodomain and an ATPase domain. Using RNAi, cancer-specific vulnerabilities have been identified in SWI/SNF-mutant tumors, including SMARCA4-deficient lung cancer; however, the contribution of conserved, druggable protein domains to this anticancer phenotype is unknown. Here, we functionally deconstruct the SMARCA2/4 paralog dependence of cancer cells using bioinformatics, genetic, and pharmacologic tools. We evaluate a selective SMARCA2/4 bromodomain inhibitor (PFI-3) and characterize its activity in chromatin-binding and cell-functional assays focusing on cells with altered SWI/SNF complex (e.g., lung, synovial sarcoma, leukemia, and rhabdoid tumors). We demonstrate that PFI-3 is a potent, cell-permeable probe capable of displacing ectopically expressed, GFP-tagged SMARCA2-bromodomain from chromatin, yet contrary to target knockdown, the inhibitor fails to display an antiproliferative phenotype. Mechanistically, the lack of pharmacologic efficacy is reconciled by the failure of bromodomain inhibition to displace endogenous, full-length SMARCA2 from chromatin as determined by in situ cell extraction, chromatin immunoprecipitation, and target gene expression studies. Furthermore, using inducible RNAi and cDNA complementation (bromodomain- and ATPase-dead constructs), we unequivocally identify the ATPase domain, and not the bromodomain of SMARCA2, as the relevant therapeutic target with the catalytic activity suppressing defined transcriptional programs. Taken together, our complementary genetic and pharmacologic studies exemplify a general strategy for multidomain protein drug-target validation and in case of SMARCA2/4 highlight the potential for drugging the more challenging helicase/ATPase domain to deliver on the promise of synthetic-lethality therapy. Cancer Res; 75(18); 3865–78. ©2015 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In all cases, the targeted proteins also harbored multiple other functional domains and are often participating in intricate protein–protein interactions that appeared to be bromodomain independent.”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [21]
In the citing paper
“While these efforts culminated in potent, specific, and well-characterized ligands for the individual bromodomains, ensuing functional analyses revealed that they are largely lacking cellular efficacy.21”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [21]
In the citing paper
“However, such inhibitors have failed to inhibit tumor cell growth [48] because the ATPase domain but not the bromodomain is essential for tumor cell growth [169].”
From Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies (2020) · cites this paper as [169]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A small molecule–kinase interaction map for clinical kinase inhibitors
Fabian, M. A., Biggs, W., Treiber, D. K., Atteridge, C. E., Azimioara, M. D., Benedetti, M. G., Carter, T. A., Ciceri, P., Edeen, P. T., Floyd, M. B., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1068 · Cited by 1,923
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870
Neuwald, A. F., Aravind, L., Spouge, J. L., & Koonin, E. V. (1999) · Genome Research · doi:10.1101/gr.9.1.27 · Cited by 1,840
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J., Baršytė-Lovejoy, D., Felletár, I., Volkmer, R., Müller, S., Pawson, T. J., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,759
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Kadoch, C., Hargreaves, D. C., Hodges, H. C., Elias, L., Ho, L., Ranish, J. A., & Crabtree, G. R. (2013) · Nature Genetics · doi:10.1038/ng.2628 · Cited by 1,493
Lessons from the Cancer Genome
Garraway, L. A., & Lander, E. S. (2013) · Cell · doi:10.1016/j.cell.2013.03.002 · Cited by 1,377
SWI/SNF nucleosome remodellers and cancer
Wilson, B. G., & Roberts, C. W. M. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3068 · Cited by 1,325
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P. S., Raine, K. M., Huang, D., Ong, C. K., Stephens, P., Davies, H. R., Jones, D., Lin, M., Teague, J. W., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,302
Targeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,298
Cited by
Sorted by citations
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097
BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562
Bromodomains: a new target class for drug development
Cochran, A. G., Conery, A. R., & Sims, R. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0030-7 · Cited by 450
Mammalian SWI/SNF Chromatin Remodeling Complexes: Emerging Mechanisms and Therapeutic Strategies
Centore, R. C., Sandoval, G. J., Soares, L. M. M., Kadoch, C., & Chan, H. M. (2020) · Trends in Genetics · doi:10.1016/j.tig.2020.07.011 · Cited by 400
An, S., & Fu, L. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.09.005 · Cited by 363
Muñoz, D. M., Cassiani, P. J., Li, L., Billy, É., Korn, J. M., Jones, M. D., Golji, J., Ruddy, D. A., Yu, K., McAllister, G., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0178 · Cited by 356
Schoenfeld, A. J., Bandlamudi, C., Lavery, J. A., Montecalvo, J., Namakydoust, A., Rizvi, H. A., Egger, J. V., Concepcion, C. P., Paul, S., Arcila, M. E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1825 · Cited by 298
Bromodomain inhibitors and cancer therapy: From structures to applications
Pérez-Salvia, M., & Esteller, M. (2016) · Epigenetics · doi:10.1080/15592294.2016.1265710 · Cited by 297
Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands
Remillard, D., Buckley, D. L., Paulk, J., Brien, G. L., Sonnett, M., Seo, H., Dastjerdi, S., Wühr, M., Dhe‐Paganon, S., Armstrong, S. A., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611281 · Cited by 293
Marked for death: Targeting epigenetic changes in cancer
Pfister, S. X., & Ashworth, A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.256 · Cited by 288
Bioinformatics and Drug Discovery
Xia, X. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666161116143440 · Cited by 264
The BAF complex in development and disease
Alfert, A., Moreno, N., & Kerl, K. (2019) · Epigenetics & Chromatin · doi:10.1186/s13072-019-0264-y · Cited by 255
Bond, M. J., & Crews, C. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00011j · Cited by 232
Papillon, J. P. N., Nakajima, K., Adair, C. D., Hempel, J., Jouk, A. O., Karki, R. G., Mathieu, S., Möbitz, H., Ntaganda, R., Smith, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01318 · Cited by 244
Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer
Zhang, H., Pandey, S., Travers, M. E., Sun, H., Morton, G. C., Madžo, J., Chung, W., Khowsathit, J., Pérez, Ó. C., Barrero, C. A., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.051 · Cited by 223
Bromodomain and extraterminal (BET) proteins: biological functions, diseases and targeted therapy
Wang, Z., Zhang, Z.-C., Wu, Y., Pi, Y., Lou, S., Liu, T., Lou, G., & Yang, C. Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01647-6 · Cited by 251
Targeted protein degradation for cancer therapy
Hinterndorfer, M., Spiteri, V. A., Ciulli, A., & Winter, G. E. (2025) · Nature reviews. Cancer · doi:10.1038/s41568-025-00817-8 · Cited by 263
Chan, K.-H., Zengerle, M., Testa, A., & Ciulli, A. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01912 · Cited by 223
Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands
Gechijian, L. N., Buckley, D. L., Lawlor, M. A., Reyes, J. M., Paulk, J., Ott, C. J., Winter, G. E., Erb, M. A., Scott, T. G., Xu, M., et al. (2018) · Nature Chemical Biology · doi:10.1038/s41589-018-0010-y · Cited by 222
Gatchalian, J., Malik, S., Ho, J., Lee, D.-S., Kelso, T. W. R., Shokhirev, M. N., Dixon, J. R., & Hargreaves, D. C. (2018) · Nature Communications · doi:10.1038/s41467-018-07528-9 · Cited by 216
Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology
Blagg, J., & Workman, P. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.005 · Cited by 207
Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors
Romero, F. A., Taylor, A. M., Crawford, T. D., Tsui, V., Côté, A., & Magnuson, S. R. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01514 · Cited by 194
Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition
Hohmann, A. F., Martin, L. J., Minder, J. L., Roe, J., Shi, J., Steurer, S., Bader, G., McConnell, D. B., Pearson, M. A., Gerstberger, T., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2115 · Cited by 190
Palmer, W. S., Poncet-Montange, G., Liu, G., Petrocchi, A., Reyna, N., Subramanian, G., Theroff, J., Yau, A., Kost-Alimova, M., Bardenhagen, J. P., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00405 · Cited by 168
Self-citationMammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities
Pierre, R. S., & Kadoch, C. (2017) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2017.02.004 · Cited by 165
Exploiting vulnerabilities of SWI/SNF chromatin remodelling complexes for cancer therapy
Wanior, M., Krämer, A., Knapp, S., & Joerger, A. C. (2021) · Oncogene · doi:10.1038/s41388-021-01781-x · Cited by 162
Fernando, T. M., Piskol, R., Bainer, R. O., Sokol, E. S., Trabucco, S. E., Zhang, Q., Trinh, H., Maund, S. L., Kschonsak, M., Chaudhuri, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19402-8 · Cited by 159
Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers
Cantley, J. L., Ye, X., Rousseau, E., Januario, T., Hamman, B. D., Rose, C. M., Cheung, T. K., Hinkle, T. B., Soto, L., Quinn, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34562-5 · Cited by 159
PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease
Kadoch, C., Copeland, R. A., & Keilhack, H. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01191 · Cited by 146
Exome-Scale Discovery of Hotspot Mutation Regions in Human Cancer Using 3D Protein Structure
Tokheim, C. J., Bhattacharya, R., Niknafs, N., Gygax, D. M., Kim, R., Ryan, M. T., Masica, D. L., & Karchin, R. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-3190 · Cited by 123
The BRG1 ATPase of Human SWI/SNF Chromatin Remodeling Enzymes as a Driver of Cancer
Wu, Q., Lian, J. B., Stein, J. L., Stein, G. S., Nickerson, J. A., & Imbalzano, A. N. (2017) · Epigenomics · doi:10.2217/epi-2017-0034 · Cited by 136
A chemical toolbox for the study of bromodomains and epigenetic signaling
Wu, Q., Heidenreich, D. J., Zhou, S., Ackloo, S. Z., Krämer, A., Nakka, K. K., Lima‐Fernandes, E., Deblois, G., Duan, S., Vellanki, R. N., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09672-2 · Cited by 124
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
He, Y., Khan, S., Huo, Z., Lv, D., Zhang, X., Liu, X., Yuan, Y., Hromas, R., Xu, M., Zheng, G., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00924-z · Cited by 126
SMARCA4: Current status and future perspectives in non-small-cell lung cancer
Tian, Y., Xu, L., Li, X., Li, H., & Zhao, M. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.216022 · Cited by 123
Epigenomic regulation of oncogenesis by chromatin remodeling
Kumar, R., Li, D.-Q., Müller, S., & Knapp, S. (2016) · Oncogene · doi:10.1038/onc.2015.513 · Cited by 117
Xue, Y., Meehan, B., Macdonald, E. A., Venneti, S., Wang, X. Q. D., Witkowski, L., Jelinic, P., Kong, T., Martínez, D., Morin, G., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-06958-9 · Cited by 119
Gerstenberger, B. S., Trzupek, J. D., Tallant, C., Fedorov, O., Filippakopoulos, P., Brennan, P. E., Fedele, V., Martin, S., Picaud, S., Rogers, C. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00012 · Cited by 113
Self-citationDiscovery of Chemical Inhibitors of Human Bromodomains
Zhang, G., Smith, S. G., & Zhou, M. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00205 · Cited by 108
Bayo, J., Fiore, E. J., Domínguez, L. M., Real, A., Malvicini, M., Rizzo, M., Atorrasagasti, C., García, M. G., Argemí, J., Martínez, E. D., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.007 · Cited by 111
Mechanistic and Structural Features of PROTAC Ternary Complexes
Casement, R., Bond, A. G., Craigon, C., & Ciulli, A. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1665-9_5 · Cited by 104
Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia
Garnar-Wortzel, L., Bishop, T. R., Kitamura, S., Milosevich, N., Asiaban, J. N., Zhang, X., Zheng, Q., Chen, E., Ramos, A. R., Ackerman, C. J., et al. (2021) · ACS Central Science · doi:10.1021/acscentsci.0c01550 · Cited by 98
Chromatin remodellers as therapeutic targets
Malone, H. A., & Roberts, C. W. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00978-5 · Cited by 119
ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies
Caumanns, J. J., Wisman, G. B. A., Berns, K., van der Zee, A. G. J., & de Jong, S. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.07.005 · Cited by 102
PROTAC degraders as chemical probes for studying target biology and target validation
Němec, V., Schwalm, M. P., Müller, S., & Knapp, S. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00478j · Cited by 98
Bromodomain Drug Discovery – the Past, the Present, and the Future
Pervaiz, M., Mishra, P., & Günther, S. (2018) · The Chemical Record · doi:10.1002/tcr.201800074 · Cited by 94
Isoform-Selective ATAD2 Chemical Probe with Novel Chemical Structure and Unusual Mode of Action
Fernández‐Montalván, A. E., Berger, M., Kuropka, B., Koo, S. J., Badock, V., Weiske, J., Puetter, V., Holton, S. J., Stöckigt, D., ter Laak, A., et al. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00708 · Cited by 92
Epigenetic regulators in cancer therapy and progression
Marei, H. E. S. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01003-7 · Cited by 116
Zhang, Z., Wang, F., Du, C., Guo, H., Ma, L., Liu, X., Kornmann, M., Tian, X., & Yang, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.05.006 · Cited by 85
Global identification of SWI/SNF targets reveals compensation by EP400
Martin, B. J. E., Ablondi, E. F., Goglia, C., Mimoso, C. A., Espinel-Cabrera, P. R., & Adelman, K. (2023) · Cell · doi:10.1016/j.cell.2023.10.006 · Cited by 85
Context-specific functions of chromatin remodellers in development and disease
Gourisankar, S. P., Krokhotin, A., Wenderski, W., & Crabtree, G. R. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00666-x · Cited by 88
Wang, H., Bierie, B., Li, A. G., Pathania, S., Toomire, K. J., Dimitrov, S. D., Liu, B., Gelman, R. S., Giobbie‐Hurder, A., Feunteun, J., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.05.038 · Cited by 80
Chromatin dependencies in cancer and inflammation
Marazzi, I., Greenbaum, B. D., Low, D. H. P., & Guccione, E. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.113 · Cited by 80
Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1
Benedetti, L. G., Cereda, M., Monteverde, L., Desai, N., & Ciccarelli, F. D. (2017) · Oncotarget · doi:10.18632/oncotarget.16838 · Cited by 81
Xue, Y., Morris, J. L., Yang, K., Fu, Z., Zhu, X., Johnson, F. D., Meehan, B., Witkowski, L., Yasmeen, A., Golenár, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25260-9 · Cited by 78
New Horizons of Synthetic Lethality in Cancer: Current Development and Future Perspectives
Previtali, V., Bagnolini, G., Ciamarone, A., Ferrandi, G., Rinaldi, F., Myers, S. H., Roberti, M., & Cavalli, A. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00113 · Cited by 84
Clinical progress and pharmacology of small molecule bromodomain inhibitors
Theodoulou, N. H., Tomkinson, N. C. O., Prinjha, R. K., & Humphreys, P. G. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2016.05.028 · Cited by 76
A Chemical Probe for the ATAD2 Bromodomain
Bamborough, P., Chung, C., Demont, E. H., Furze, R. C., Bannister, A. J., Che, K. H., Diallo, H., Douault, C., Grandi, P., Kouzarides, T., et al. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201603928 · Cited by 75
Gong, W., Luo, C., Peng, F., Xiao, J., Zeng, Y., Yin, B., Chen, X., Li, S., He, X., Liu, Y., et al. (2021) · Clinical Science · doi:10.1042/cs20210447 · Cited by 75
Sahafnejad, Z., Ramazi, S., & Allahverdi, A. (2023) · Genes · doi:10.3390/genes14040873 · Cited by 73
Lang, J. D., Hendricks, W. P. D., Yin, H., Kiefer, J. M., Ramos, P. M., Sharma, R., Pirrotte, P., Raupach, E. A., Sereduk, C., Tang, N., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1928 · Cited by 72
Yang, L., Tu, W., Huang, L., Miao, B., Kaneshige, A., Jiang, W., Leng, L., Wang, M., Wen, B., Sun, D., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00953 · Cited by 67
Transforming targeted cancer therapy with PROTACs: A forward-looking perspective
Farnaby, W., Koegl, M., McConnell, D. B., & Ciulli, A. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.02.009 · Cited by 66
BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma
Panditharatna, E., Marques, J. G., Wang, T., Trissal, M. C., Liu, I., Jiang, L., Beck, A., Groves, A. P., Dharia, N. V., Li, D., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1491 · Cited by 68
Wu, Q., Sharma, S., Cui, H., LeBlanc, S. E., Zhang, H., Muthuswami, R., Nickerson, J. A., & Imbalzano, A. N. (2016) · Oncotarget · doi:10.18632/oncotarget.8384 · Cited by 62
Self-citationBromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development
Jeffers, V., Yang, C., Huang, S., & Sullivan, W. J. (2017) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00047-16 · Cited by 61
Kanjee, U., Grüring, C., Chaand, M., Lin, K., Egan, E. S., Manzo, J., Jones, P. L., Yu, T. M., Barker, R. H., Weekes, M. P., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711310114 · Cited by 63
Self-citationTargeting Chromatin-Remodeling Factors in Cancer Cells: Promising Molecules in Cancer Therapy
Zhang, F.-L., & Li, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112815 · Cited by 63
Gaudio, N. D., Costanzo, A. D., Liu, N. Q., Conte, L., Migliaccio, A., Vermeulen, M., Martens, J. H. A., Stunnenberg, H. G., Nebbioso, A., & Altucci, L. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1570-9 · Cited by 61
Fast-acting chemical tools to delineate causality in transcriptional control
Jaeger, M. G., & Winter, G. E. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.015 · Cited by 62
Targeting epigenetic modulators using PROTAC degraders: Current status and future perspective
Webb, T., Craigon, C., & Ciulli, A. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128653 · Cited by 58
Targeting synthetic lethal paralogs in cancer
Ryan, C. J., Mehta, I., Kebabci, N., & Adams, D. J. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.02.002 · Cited by 59
Galdeano, C., & Ciulli, A. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0059 · Cited by 59
Chromatin Remodeling Factor BRG1 Regulates Stemness and Chemosensitivity of Glioma Initiating Cells
Ganguly, D., Sims, M. M., Cai, C., Fan, M., & Pfeffer, L. M. (2018) · Stem Cells · doi:10.1002/stem.2909 · Cited by 59
Using Chemical Epigenetics to Target Cancer
Wimalasena, V. K., Wang, T., Sigua, L. H., Durbin, A. D., & Qi, J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.04.023 · Cited by 55
Myrianthopoulos, V., Gaboriaud‐Kolar, N., Tallant, C., Hall, M. L., Grigoriou, S., Brownlee, P. M., Fedorov, O., Rogers, C. M., Heidenreich, D. J., Wanior, M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00355 · Cited by 55
Laubscher, D., Gryder, B. E., Sunkel, B. D., Andrésson, Þ., Wachtel, M., Das, S., Roschitzki, B., Wolski, W., Wu, X., Chou, H.-C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27176-w · Cited by 58
Gelato, K. A., Adler, D., Ocker, M., & Haendler, B. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1134490 · Cited by 52
Kurashima, K., Kashiwagi, H., Shimomura, I., Suzuki, A., Takeshita, F., Mazevet, M., Harata, M., Yamashita, T., Yamamoto, Y., Kohno, T., et al. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa005 · Cited by 53
Development of PROTAC Degrader Drugs for Cancer
Vetma, V., O’Connor, S., & Ciulli, A. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061824-105806 · Cited by 55
BRG1 is a prognostic indicator and a potential therapeutic target for prostate cancer
Muthuswami, R., Bailey, L. O., Radhakrishnan, R., Imbalzano, A. N., Nickerson, J. A., & Hockensmith, J. W. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28161 · Cited by 49
Ehrenhöfer-Wölfer, K., Puchner, T., Schwarz, C., Rippka, J., Blaha-Ostermann, S., Strobl, U., Hörmann, A., Bader, G., Kornigg, S., Zahn, S. K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-48152-x · Cited by 51
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
Drug Discovery and Chemical Biology of Cancer Epigenetics
Ribich, S. A., Harvey, D. M., & Copeland, R. A. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.020 · Cited by 50
The mechanisms of action of chromatin remodelers and implications in development and disease
Sahu, R. K., Singh, S., & Tomar, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114200 · Cited by 50
Čermáková, K., & Hodges, H. C. (2018) · Molecules · doi:10.3390/molecules23081958 · Cited by 51
Sophisticated Conversations between Chromatin and Chromatin Remodelers, and Dissonances in Cancer
Clapier, C. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115578 · Cited by 46
The role of chromatin remodeler SMARCA4/BRG1 in brain cancers: a potential therapeutic target
Navickas, S. M., Giles, K. A., Brettingham‐Moore, K. H., & Taberlay, P. C. (2023) · Oncogene · doi:10.1038/s41388-023-02773-9 · Cited by 46
Progress in the Development of non‐BET Bromodomain Chemical Probes
Theodoulou, N. H., Tomkinson, N. C. O., Prinjha, R. K., & Humphreys, P. G. (2016) · ChemMedChem · doi:10.1002/cmdc.201500540 · Cited by 45
Control of Stimulus-Dependent Responses in Macrophages by SWI/SNF Chromatin Remodeling Complexes
Gatchalian, J., Liao, J., Maxwell, M. B., & Hargreaves, D. C. (2020) · Trends in Immunology · doi:10.1016/j.it.2019.12.002 · Cited by 45
Berlin, M. Y., Cantley, J. L., Bookbinder, M., Bortolon, E., Broccatelli, F., Cadelina, G., Chan, E. W., Chen, H., Chen, X., Cheng, Y., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01781 · Cited by 43
The Emerging Roles of ATP-Dependent Chromatin Remodeling Complexes in Pancreatic Cancer
Hasan, N. M., & Ahuja, N. (2019) · Cancers · doi:10.3390/cancers11121859 · Cited by 48
Pan-SMARCA/PB1 Bromodomain Inhibitors and Their Role in Regulating Adipogenesis
Wanior, M., Preuß, F., Ni, X., Krämer, A., Mathea, S., Göbel, T., Heidenreich, D. J., Simonyi, S., Kahnt, A. S., Joerger, A. C., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01242 · Cited by 43
Dysregulation of chromatin remodelling complexes in amyotrophic lateral sclerosis
Tibshirani, M., Zhao, B., Gentil, B. J., Minotti, S., Marques, C., Keith, J., Rogaeva, E., Zinman, L., Rouaux, C., Robertson, J., et al. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx301 · Cited by 42
Degraders in epigenetic therapy: PROTACs and beyond
Dai, X., Ji, S., Fu, M., Liu, G.-Z., Liu, H., Wang, S., Shen, L., Wang, N., Herdewijn, P. A., Zheng, Y., et al. (2024) · Theranostics · doi:10.7150/thno.92526 · Cited by 45
Surdziel, E., Clay, I., Nigsch, F., Thiemeyer, A., Allard, C., Hoffman, G. R., Reece-Hoyes, J. S., Phadke, T., Gambert, R., Keller, C. G., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183679 · Cited by 42
BRG1 in the Nucleus Accumbens Regulates Cocaine-Seeking Behavior
Wang, Z.-J., Martin, J. A., Mueller, L. E., Caccamise, A. J., Werner, C. T., Neve, R. L., Gancarz, A. M., Li, J., & Dietz, D. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.04.020 · Cited by 41
Zhan, Y., Kost‐Alimova, M., Shi, X., Leo, E., Bardenhagen, J., Shepard, H. E., Appikonda, S., Vangamudi, B., Zhao, S., Tieu, T. N., et al. (2015) · Epigenetics & Chromatin · doi:10.1186/s13072-015-0026-4 · Cited by 41
Self-citationZeng, X., Yao, B., Liu, J., Gong, G., Liu, M., Li, J., Pan, H., Li, Q., Yang, D., Lu, P., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00367-y · Cited by 41
Rago, F., Elliott, G., Li, A., Sprouffske, K., Kerr, G., Desplat, A., Abramowski, D., Chen, J. T., Farsidjani, A., Xiang, K. X., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1013 · Cited by 40
Polycomb and trithorax opposition in development and disease
Poynter, S. T., & Kadoch, C. (2016) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.244 · Cited by 43
Metadata
- Authors
- Vangamudi, B., Paul, T. A., Shah, P. K., Kost-Alimova, M., Nottebaum, L., Shi, X., Zhan, Y., Leo, E., Mahadeshwar, H. S., Protopopov, A., Futreal, A., Tieu, T. N., Peoples, M., Heffernan, T. P., Marszalek, J. R., Toniatti, C., Petrocchi, A., Verhelle, D., Owen, D. R., Draetta, G., Jones, P., Palmer, W. S., Sharma, S., & Andersen, J. N.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Pfizer (United States) (US)
- 1Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- 3Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Corresponding author
- Sharma, Shikhar
- Andersen, Jannik N.
- ORCID
- Venue
- Cancer Research
- Published
- 2015-09-14
- Volume
- 75
- Issue
- 18
- Pages
- 3865-3878
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- PMC
- PMC4755107
- OpenAlex
- W2137511124
- Cited by
- 281
- References
- 50
- Citations by year
- 2026: 22 · 2025: 31 · 2024: 28 · 2023: 36 · 2022: 22 · 2021: 24 · 2020: 25 · 2019: 19 · 2018: 20 · 2017: 26 · 2016: 22 · 2015: 6
- FWCI
- 11.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Association for Cancer Research
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- National Cancer Institute (P30CA016672)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- SMARCA2, SMARCA4, SWI/SNF complex, ATPase domain, bromodomain, bromodomain inhibitors, drug target validation, synthetic lethality, chromatin binding, cDNA rescue, rhabdoid tumor, synovial sarcoma, leukemia, transcriptional programs, chromatin immunoprecipitation
- MeSH terms
- Binding, Competitive, Catalysis, Chromatin, Chromosomal Proteins, Non-Histone, DNA Helicases, Genetic Complementation Test, Humans, Lung Neoplasms, Neoplasm Proteins, Neoplasms, Nuclear Proteins, Pyridines, Sarcoma, Synovial, Transcription Factors, Protein Structure, Tertiary, DNA, Complementary, Rhabdoid Tumor, RNA Interference, RNA, Small Interfering, Chromatin Assembly and Disassembly, Cell Line, Tumor, Microarray Analysis, Azabicyclo Compounds, Gene Knockout Techniques, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
